Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: a real-life experience

Kawamatawong, Theerasuk; Poachanukoon, Orapan; Boonsiri, Chalermporn; Saengasapaviriya, Atik; Sittipunt, Chanchai; Chantaphakul, Hiroshi; Maneechotesuwan, Kittipong; Ngamchanyaporn, Pintip; Piyavechviratana, Kunchit; Yongjaiyut, Praparn; Khanisap, Apichart; Juthong, Siwasak; Rithirak, Warangkana; Pornsuriyasak, Prapaporn; Pothirat, Chaicharn; Boonsawat, Watchara

doi:10.12932/ap0872

Cited by 5 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To minimize bias, non-significant results reported in the original publication were included in our pooled estimates. Table 1 summarizes the 42 studies stratified by 30 adult-only studies [24,26,27,[30][31][32][33][34][35][36][37][40][41][42][43][44][45][46][47][58][59][60][61][62][63][64][65][66][67][68] (n = 3558) and 12 adult/ adolescent studies [25,38,39,56,57,[69][70][71][72][73][74][75][76][77] (n = 5819). These 42 studies comprised a total of 9377 patients from 35 countries: 25 in Europe (incl.…”

Section: Other Methodological Considerationsmentioning

confidence: 99%

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

MacDonald

Kavati

Ortiz

et al. 2019

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008-2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation. Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing. ARTICLE HISTORY

show abstract

Section: Other Methodological Considerationsmentioning

confidence: 99%

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

MacDonald

Kavati

Ortiz

et al. 2019

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Por exemplo, o uso concomitante de Omalizumabe com corticosteroides inalados pode permitir uma redução na dose de corticosteróides necessária para controlar a asma, minimizando assim os efeitos colaterais associados ao uso prolongado desses medicamentos. Em relação ao perfil de segurança, não foram observados efeitos colaterais graves em nenhum dos tratamentos (KAWAMATAWONG T, et al, 2018). No entanto, a falta de dados de longo prazo sobre segurança é uma limitação (AGACHE I, et al, 2020).…”

Section: Discussionunclassified

Avaliação da eficácia das terapias biológicas com anticorpos monoclonais na asma severa

Oliveira,

Mameri,

Moreira

et al. 2023

Acervo Saúde

View full text Add to dashboard Cite

Objetivo: Analisar a eficiência das terapias biológicas com anticorpos monoclonais em pacientes com asma severa. Métodos: Esse estudo é uma revisão integrativa e foi realizada avaliando a literatura disponível na plataforma PubMed Central com os seguintes termos de pesquisa MeSH: Monoclonal Antibodies, Asthma; com o objetivo responder se a eficácia das terapias biológicas com anticorpos monoclonais no tratamento de asma severa é superior aos tratamentos convencionais. Inicialmente foram selecionados 1339 artigos na íntegra publicados entre 2018 e 2023, em inglês, português e espanhol. Após critérios de inclusão foram removidos artigos duplicados, resumos e aqueles que não atendiam os critérios de seleção, restando 26 artigos que foram incluídos nesta revisão. Resultados: Foi evidenciados o benefício de anticorpos como benralizumab, reslizumab, mepolizumab, dupilimabe e omalizumabe, pois eles se mostram eficientes na redução das exacerbações graves de asma quando comparados com corticoides inalatórios e orais no tratamento desses pacientes. Considerações finais: Embora ainda sejam necessários mais estudos sobre o assunto, as melhorias no controle da asma severa com anticorpos monoclonais, utilizando questionários validados, foram significativas, em comparação com os tratamentos habituais, na maioria dos estudos avaliados.

show abstract

Anti-IgE Significantly Changes Circulating Interleukin-25, Vitamin-D and Interleukin-33 Levels in Patients with Allergic Asthma

Yalçın

Uzun²

2019

CPD

View full text Add to dashboard Cite

Background: Multi-center, randomized-controlled trials and observational studies have demonstrated that, in severe asthmatic patients receiving omalizumab treatment, the frequency of exacerbations, the number of urgent adverse events, and the need for oral steroids tend to decrease. Material and Method: This study included a total of 32 patients. The patients were divided into two groups as Group IA (pre-omalizumab) and Group IB (post-omalizumab). Serum IL-25 and IL-33 levels were measured and the number of emergency admissions, length of hospitalization (day), Asthma Control Test (ACT) scores, eosinophil cationic protein (ECP), and fractional exhaled nitric oxide (FeNO) value were analyzed. Results: ACT and FeNO values increased after omalizumab treatment, while IL-33, IL-25 levels decreased after the completion of omalizumab treatment. Furthermore, there was a weak, positive, and significant relationship between the changes in the ECP levels and IL-33 levels (r=0.38, p=0.03). Conclusion: To the best of our knowledge, this is the first study to compare circulating IL-25 and IL-33 levels with specific IgE synthesis in the literature. Multivariate correlation analysis showed that the changes in serum IL-33 levels were significantly correlated with the changes in the mite sIgE levels and length of hospital stay (Fmodel=11.2, p=0.01, r2=0.45). On the other hand, there was no significant relationship between the other variables and changes in the IL-25 levels.

show abstract

Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: a real-life experience

Abstract: Background: To evaluate long-term effectiveness of omalizumab in 'real-life' setting of Thai asthmatic patients.

Cited by 5 publications

References 29 publications

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

Avaliação da eficácia das terapias biológicas com anticorpos monoclonais na asma severa

Anti-IgE Significantly Changes Circulating Interleukin-25, Vitamin-D and Interleukin-33 Levels in Patients with Allergic Asthma

Contact Info

Product

Resources

About